期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2015年圣安东尼奥国际乳腺癌研讨会回顾 被引量：2

Review of 2015 San Antonio Breast Cancer Symposium
原文传递
导出
摘要 笔者选取了2015年圣安东尼奥国际乳腺癌会议研讨的一些热点话题,包括乳腺癌化疗、新辅助化疗、分子靶向治疗及免疫治疗,简要介绍了本次大会公布的多项研究结果,以期为广大临床医师提供参考,推进乳腺癌治疗的标准化、规范化。 This article selected some hot topics discussed in San Antonio Breast Cancer Symposium in 2015, including chemotherapy, neoadjuvant chemotherapy, molecular targeted therapy and immunotherapy for breast cancer patients, and briefly introduced several significant findings presented at the conference in order to provide references to medical staff of breast care and improve the standardization and normalization of breast cancer treatment in the future.
作者 张瑾 魏嘉阳
机构地区 天津医科大学肿瘤医院乳腺三科
出处 《中华乳腺病杂志（电子版）》 CAS CSCD 2016年第1期6-9,共4页 Chinese Journal of Breast Disease(Electronic Edition)
关键词 乳腺肿瘤 化学疗法 辅助 免疫疗法 分子靶向治疗 Breast neoplasms Chemotherapy, adjuvant Immunotherapy Molecular targetedtherapy
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Liu FF, Shi W, Done SJ, et al. Identification of a low-risk luminal Abreast cancer cohort that may not benefit from breast radiotherapy [ J].J Clin Oncol, 2015,33(18); 2035-2040.
  • 2Slamon D, Eiermann W, Robert N, et al. Ten year follow-up of theBCIRG-006 trial comparing doxorubicin plus cyclophosphamide followedby docetaxel (AC-T) with doxorubicin plus cyclophosphamide followedby docetaxel and trastuzumab ( AC-TH) with docetaxel, carboplatinand trastuzumab (TCH) in HER2 + early breast cancer patients [ EB/OL]. [ 2016-01-05 ]. http://www. abstracts2view. com/sabcsl5/view, php? nu = SABCS15L_1030&terms.
  • 3Toi M, Lee SJ, Lee ES, et al. A phase IQ trial of adjuvant capecitabinein breast cancer patients with HEH2-negative pathologic residualinvasive disease after neoadjuvant chemotherapy (CREATE-X,JBCRG-04) [EB/OL]. [ 2016-01-05 ]. http://www. abstracts2view. com/sabcsl5/view. php? nu = SABCS15L_1229&terms.
  • 4von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvantcarboplatin in patients with triple-negative and HER2-positive earlybreast cancer ( GeparSixto; GBG 66) : a randomised phase 2 trial [ J].Lancet Oncol, 2014,15(7) :747-756.
  • 5Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvantchemotherapy in stage II -ID triple negative breast cancer on eligibilityfor breast-conserving surgery and breast conservation rates : surgicalresults from CALGB 40603 (Alliance) [J]. Ann Surg, 2015, 262(3):434439.
  • 6No authors listed. Tumor-infiltrating lymphocytes and associations withpathological complete response and event-free survival in HER2-positiveearly-stage breast cancer treated with lapatinib and trastuzumab : asecondary analysis of the NeoALTTO trial [J]. JAMA Oncol, 2015,1(4) ;544.
  • 7Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer(ExteNET ) : a multicentre,randomised,double-blind,placebo-controlled ,phase 3 trial [EB/OL]. [ 2016-01-05 ]. http://www.sciencedirect. com/science/article/pii/S1470204515005513.
  • 8Boyraz B, Sendur MA, Aksoy S, et al. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer [ J]. C urr Med Res Opin, 2013, 29(4) : 405-414.
  • 9Hein A, Lambrechts D, von Minckwitz G, et al. Genetic variants inVEGF pathway genes in neoadjuvant breast cancer patients receivingbevacizumab : Results from the randomized phase M GeparQuinto study[J]. Int J Cancer, 2015, 137(12):2981-2988.
  • 10Vansteenkiste JF, Canon JL, Braud FD, et al. Safety and efficacy ofBuparlisib ( BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study [ J].J Thorac Oncol, 2015, 10(9) :1319-1327.

同被引文献18

引证文献2

二级引证文献4

中华乳腺病杂志（电子版）
2016年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部